Crafton Biotechnology
June 24, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Platform for Therapeutics
Crafton Biotechnology is a privately held mRNA therapeutics company developing next-generation vaccines and treatments powered by its proprietary PureCap® and CRAFT™ platforms. PureCap® enables GMP production of ultra-pure, fully capped mRNA with industry-leading capping efficiency, ultra-low dsRNA impurities, and higher protein expression than conventional approaches. CRAFT™ supports rapid, de novo chemical synthesis of capped mRNA in as little as one week, without requiring a DNA template, while expanding access to novel chemical modifications. Leveraging these technologies, Crafton is advancing a pipeline of mRNA programs in oncology and infectious disease, including off-the-shelf cancer vaccines and a COVID-19 candidate expected to enter the clinic in 2027.
Company HQ City:
Palo Alto
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2022
CEO
Hayato Watanabe
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}